💊
Alhemo
concizumab
Hemophilia A;Hemophilia B
✅ Authorised
✅
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Alhemo is indicated for routine prophylaxis of bleeding in patients 12 years of age or more with: • haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors.• severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without FVIII inhibitors.• haemophilia B (congenital factor IX deficiency) with FIX inhibitors.• moderate/severe haemophilia B (congenital factor IX deficiency, FIX ≤ 2%) without FIX inhibitors.
⚠️ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo